Milken Institute panel on Universal Flu Vaccine (2019)

Universal Flu Vaccine

THIS WAS IN LATE 2019, NOTE.

 

Milken Institute Future of Health Summit 2019.*

         https://milkeninstitute.org/events/future-of-health-summit-2019/overview

         2021

Bright, Rick, Anthony S. Fauci, Bruce Gellin, Margaret A. Hamburg, Michael Specter and Casey Wright. "Universal Flu Vaccine." C-Span 29 Oct. 2019.*

         https://www.c-span.org/video/?465845-1/universal-flu-vaccine

         2021

Health experts discussed the scientific and technological prospects of an effective universal influenza vaccine. Speakers included Dr. Anthony Fauci, director of the National Institute of Allergy and Infectious Diseases and Margaret Hamburg, former FDA commissioner. Panelists discussed the need for more funding for research, better collaboration between the private and government sectors, advances in technology in flu research and the goal of a universal flu vaccine.

For the revealing section on the Plandemic, begin c. minute 15. 

_____."New Video emerges Milken Institute Future of Health Summit October 2019." Video. Headon Enterprises.*

         https://youtu.be/UbgKwbuzsd4

         2021

C. minute 30, Rick Bright speaks. They need to make vaccines sexy again for research and funding, with a disruptive event that does away with the paperwork:

THAT'S OUR BEST CHALLENGE THAT TO MAKE IT SEXY I THINK WE HAVE TO, I LIKE THE CONCEPT DISRUPTING THE FIELD . IF WE ARE JUST CONTINUALLY THINKING WE'RE GOING TO WORK ON ANOTHER ITERATION OR NO OFFENSE, I THINK WE NEED TO CONTINUE WHAT WE'RE DOING ANOTHER ITERATION OR ANOTHER ASSAY OR ANOTHER STEP, I DON'T KNOW IF THAT'S ENOUGH TO EXCITE AS CREATIVE THINKERS SO IN ADDITION TO DOING WHAT WE'RE DOING, WE'RE SO GLAD , I THINK IN PARALLEL THERE MIGHT BE A NEED OR EVEN AN URGENT CALL FOR AN ENTITY OF EXCITEMENT OUT THERE THAT'S COMPLETELY DISRUPTIVE , THAT'S NOT BEHOLDEN TO BUREAUCRATIC STRINGS AND PROCESSES . 

 

They need to make flu sexy again, a new unprecedented model of collaboration, they need to shock the public with something not boring like the flu.

 ABSOLUTELY THE SAD TRUTH IS WHEN THERE'S A MAJOR CRISIS THE FOCUS IS ATTENTION AND USUALLY RESOURCES AND SOME SIGNIFICANT MOBILIZATION POLICY. IT DOESN'T NECESSARILY MEAN THAT WE ARE USING RESOURCES AND THE BEST WAY POSSIBLE THOUGH BECAUSE IT DONE IN THE MOMENT OF CRISIS. AND THERE'S THROWING MONEY AT THINGS THAT SOUNDS GOOD WITHOUT ME AND THEM BEING THOUGHT THROUGH AND THEN THERE'S WHAT WE USED TO CALL THE U-SHAPED CURVE OF CONCERN WHERE INITIAL INCREASE IN RESOURCES AND THEN WHEN THE PROBLEM STAYS AND OTHER PROBLEMS EMERGE INSTEAD, EVERYTHING DROPS OFF .  

 I'M NOT GOING TO SAY WE ARE FAR AWAY BUT I DON'T THINK IT'S TOO CRAZY. IF WE WENT TOWARDS THE AREA OF SYNTHETIC-BASED VACCINES AND REMOVE THE DEPENDENCY OF MAKING THE VACCINE HAS TO BE SOMETHING THAT WE HAVE TO GROW INTO SOMETHING ELSE AN EGG OR CELL OR AN INSECT CELL OR ANY DEPENDENCY ON GROWTH IF WE CAN MOVE INTO A MORE SYNTHETIC MESSENGER RNA BASE THOSE SEQUENCES CAN BE GRAPHICALLY SHARED AROUND THE WORLD. IN TIMES THAT CAN SYNTHESIZE THE SMALL FRAGMENTS OF MESSENGER RNA CAN BE MADE IN A SHOEBOX SIZED SYSTEM RIGHT NOW WHICH IS TRANSLATABLE INTO A 3-D PRINTER OR INJECT PRINTER. PUTTING THOSE IN A SYSTEM TO PRINT THOSE A SELF ADMINISTERED VACCINE COULD HAPPEN THAT TECHNOLOGIES ARE OUT THERE. WE HAVEN'T DEMONSTRATED THE TRUE EFFECTIVENESS AND ABILITY OF THE VACCINE BUT IT'S NOT TOO CRAZY TO THINK THAT AN OUTBREAK OF NOT ONLY A VIRUS THAT OCCURRED IN CHINA SOMEWHERE, WE COULD GET THIS RNA SEQUENCE FROM BAD AND BEAM IT TO A NUMBER OF REGIONAL CENTERS IF NOT LOCAL AND IT'S NOT EVEN IN YOUR HOME AT SOME POINT IN. THOSE VACCINES AND SELF ADMINISTERED. THE TECHNOLOGY IS THERE TO BE ADAPTED AND ASSEMBLED AND PUT INTO THAT FUTURISTIC VIEW OF RAPID RESPONSE TO AN EMERGING THREAT. 

On incentives to companies. We've got to reduce their risks or guarantee purchase, making more predictable the regulatory questions....

 I THINK THERE ARE CERTAINLY COMPANIES BIG AND SMALL THAT ABSOLUTELY WOULD. I THINK WE HAVE SEEN YOU HAD MENTIONED THE EBOLA OUTBREAK. WE HAVE SEEN SEVERAL MAJOR COMPANIES AND SMALLER ONE STEP UP TO THE PLATE IN WAYS THAT AREN'T REALLY BENEFITING THEIR BOTTOM LINE THAT ARE IMPORTANT IN TERMS OF PUBLIC HEALTH. BUT I THINK WE DO HAVE TO TRY TO CREATE A CONTEXT FOR THEM TO DO THIS AND WHICH THEY WILL GET REWARDED. SOME OF IT IS APPRECIATION. SOME OF IT IS THE SENSE OF CONTRIBUTING AND REALLY HARNESSING SCIENCE AND THE BENEFIT OF HUMANITY AND SOME OF IT IS HOPING TO DECREASE SOME OF THE BARRIERS AND THE UNCERTAINTY IN THE PROCESS. I THINK THAT GOES BACK TO THE COLLABORATION. I THINK WHAT WE REALLY HAVE TO DO ABOUT IT IS HOW TO ALIGN THE DIFFERENT CAPABILITIES THE DIFFERENT FUNDING STREAMS AND DIFFERENT INCENTIVES TOWARD A COMMON GOAL. FOR AN INDUSTRY I THINK IT IS REALLY IMPORTANT FOR THEM TO NOT FEEL THAT THEY ARE JUST GOING TO SORT OF WALK OFF A CLIFF WITH A COMPLETELY NEW APPROACH WITHOUT ANY IDEA WHETHER WE'LL BE SUCCESSFUL. WHAT WE HAVE SEEN IN VARIOUS AREAS AND CERTAINLY SOMETHING WE'LL I LEARNED WHEN I WAS COMMISSIONER OF THE FOOD AND DRUG ADMINISTRATION THE SOONER EVERYBODY CAN SIT AT THE TABLE, GOVERNMENT INDUSTRY ACADEMICS, RESEARCHERS IN AND IN MANY CASES THE PEOPLE WHO ARE GOING TO HAVE TO EITHER CONSUME OR DELIVER THE PRODUCT AND REALLY TOGETHER MAP OUT A PLAN AND IDENTIFY WHAT ARE THE CRITICAL QUESTIONS TO ASK AND ANSWER? WHAT ARE THE UNKNOWNS SCIENTIFICALLY IN THE UNKNOWNS IN TERMS OF THE REGULATORY PROCESS AND WHAT IS THE LEVEL OF RISK THAT PEOPLE ARE WILLING TO ACCEPT AND HOW CAN WE REDUCE SOME OF THAT EITHER THROUGH FINANCIAL INCENTIVES OR GUARANTEED PURCHASE OR YOU KNOW REALLY CLARIFYING AND MAKE YOU MORE PREDICTABLE THE REGULATORY QUESTIONS AS WELL.  

 Philanthropy will help, they trust. I gather they are thinking about Gates-style philanthropy.

—oOo—